Department of Radiation Oncology, Erciyes University Medical Faculty, Kayseri, Turkey.
Eur J Cancer Care (Engl). 2013 Jan;22(1):133-40. doi: 10.1111/ecc.12010. Epub 2012 Sep 19.
The aim of this study was to examine the effect of being overweight on survival in patients with gastric cancer undergoing adjuvant chemoradiotherapy and chemotherapy. In this study 152 patients were evaluated. Radiotherapy dose was 45 Gy given in 5 weeks. 5-FU 425 mg/m(2) and folinic acid 20 mg/m(2) were administered weekly during the radiotherapy and four cycles with 4-week intervals as consolidation chemotherapy after radiotherapy. Patients were assigned into two groups according to their body mass index: overweight (body mass index ≥25 kg/m(2)) and normal weight (body mass index <25.0 kg/m(2)). The median overall survival was 39 months vs. 18 months and median disease-free survival was 27 months vs. 13 months in the overweight and normal-weight groups respectively (P = 0.004 and P = 0.006 respectively). The 5-year survival was better in the patients with overweight than those with normal weight (42% vs. 17%; P = 0.004). The overall survival was significantly better with being overweight and early pathological stage (P = 0.016 and P = 0001 respectively). Overall survival, disease-free survival and long-term survival in patients with gastric cancer undergoing adjuvant treatment were better in overweight than normal-weight patients. Moreover, it was shown that body mass index and pathological stage were associated to survival and prognosis.
本研究旨在探讨超重对接受辅助放化疗的胃癌患者生存的影响。本研究共评估了 152 例患者。放疗剂量为 45 Gy，分 5 周给予。5-FU 425 mg/m(2)和亚叶酸钙 20 mg/m(2)在放疗期间每周给予，放疗后 4 周间隔进行 4 个周期的巩固化疗。根据体重指数（BMI）将患者分为两组：超重（BMI≥25 kg/m(2))和正常体重（BMI<25.0 kg/m(2))。超重组的中位总生存期为 39 个月，而正常体重组为 18 个月（P=0.004）；超重组的中位无病生存期为 27 个月，正常体重组为 13 个月（P=0.006）。超重患者的 5 年生存率高于正常体重患者（42% vs. 17%；P=0.004）。超重和早期病理分期的总生存期显著改善（P=0.016 和 P=0001 分别）。接受辅助治疗的胃癌患者的总生存期、无病生存期和长期生存均优于正常体重患者。此外，还表明 BMI 和病理分期与生存和预后相关。
